Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2023-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce material events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company announced its financial results for the third quarter ended September 30, 2023. It also references a press release (Exhibit 99.1) containing the financial results. The document itself is short (3596 characters) and primarily serves to furnish the press release rather than containing detailed financial statements or analysis. According to the rules, such a document announcing quarterly financial results via a press release in a Form 8-K is classified as an Earnings Release (ER).
2023-11-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 24, 2023, by IDEAYA Biosciences, Inc. The content describes an underwriting agreement for a public offering of common stock and pre-funded warrants, including details about the number of shares, pricing, underwriters, and closing of the offering. It also references exhibits related to the underwriting agreement, warrant form, and legal opinion. The primary focus is on the company's capital raising activity through a stock offering. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not a full financial report, earnings release, or regulatory filing of another type, but specifically details a financing transaction. The document length (6574 characters) supports it being a substantive filing rather than a brief announcement or certification. Therefore, the correct classification is CAP with high confidence.
2023-10-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and pre-funded warrants by IDEAYA Biosciences, Inc. It includes detailed offering terms, underwriting information, risk factors, and use of proceeds. The document is a registration and offering prospectus supplement, which is a capital markets document related to fundraising and securities issuance. It is not a financial report, earnings release, management discussion, or any other type of corporate report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a capital raising filing.
2023-10-26 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a securities offering by IDEAYA Biosciences, Inc. It includes information about the offering of common stock and pre-funded warrants, underwriting details, risk factors, use of proceeds, and legal matters. The document references a registration statement filed with the SEC under Form S-3 and is dated October 24, 2023. The content is typical of a capital raising filing, specifically a prospectus supplement for a public offering of securities. There is no indication of financial results, management discussion, audit reports, or other report types. The document is clearly a capital/financing update related to a securities offering.
2023-10-24 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content includes preliminary financial estimates for the quarter ended September 30, 2023, and an update on an 'at-the-market' equity offering program. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) but rather provides a brief update on financial condition and capital raising activities. The document is about ongoing financial condition and capital structure updates, specifically mentioning the ATM equity offering and preliminary cash balances. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is just over 5,000 characters and contains substantive information, not merely an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear content and form type.
2023-10-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.